Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Amicus Therapeutics Analyst Ratings and Price Targets | NASDAQ:FOLD | Benzinga
Amicus Therapeutics Inc has a consensus price target of $16.25 based on the ratings of 13 analysts. The high is $22 issued by UBS on May 2, 2025. The low is $9 issued by Goldman Sachs on May 2, 2025. The 3 most-recent analyst ratings were released by UBS, Goldman Sachs, and Wells Fargo on May 2, 2025, May 2, 2025, and February 20, 2025, respectively. With an average price target of $16 between UBS, Goldman Sachs, and Wells Fargo, there's an implied 162.51% upside for Amicus Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
Goldman Sachs
Wells Fargo
Cantor Fitzgerald
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Amicus Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/02/2025 | Buy Now | 260.95% | UBS | Karl Chalabala28% | $21 → $22 | Maintains | Buy | Get Alert |
| 05/02/2025 | Buy Now | 47.66% | Goldman Sachs | Salveen Richter51% | $12 → $9 | Maintains | Neutral | Get Alert |
| 02/20/2025 | Buy Now | 178.92% | Wells Fargo | Tiago Fauth42% | $18 → $17 | Maintains | Overweight | Get Alert |
| 02/20/2025 | Buy Now | — | Needham | Gil Blum49% | — | Reiterates | Hold → Hold | Get Alert |
| 01/15/2025 | Buy Now | 244.54% | Cantor Fitzgerald | Kristen Kluska66% | $21 → $21 | Reiterates | Overweight → Overweight | Get Alert |
| 01/13/2025 | Buy Now | — | Needham | Gil Blum49% | — | Reiterates | Hold → Hold | Get Alert |
| 12/13/2024 | Buy Now | 96.88% | Morgan Stanley | Jeffrey Hung49% | $17 → $12 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/12/2024 | Buy Now | 178.92% | JP Morgan | Anupam Rama57% | $16 → $17 | Maintains | Overweight | Get Alert |
| 11/07/2024 | Buy Now | 244.54% | UBS | Karl Chalabala28% | $19 → $21 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | 146.1% | Guggenheim | Debjit Chattopadhyay50% | $13 → $15 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | 244.54% | Cantor Fitzgerald | Kristen Kluska66% | $20 → $21 | Maintains | Overweight | Get Alert |
| 11/07/2024 | Buy Now | — | Needham | Gil Blum49% | — | Reiterates | → Hold | Get Alert |
| 10/17/2024 | Buy Now | 146.1% | B of A Securities | Tazeen Ahmad53% | $13 → $15 | Maintains | Buy | Get Alert |
| 10/11/2024 | Buy Now | 195.32% | Morgan Stanley | Jeffrey Hung49% | $19 → $18 | Maintains | Overweight | Get Alert |
| 09/20/2024 | Buy Now | 228.14% | Cantor Fitzgerald | Kristen Kluska66% | $20 → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 09/06/2024 | Buy Now | 195.32% | Jefferies | Dennis Ding16% | → $18 | Initiates | → Buy | Get Alert |
| 08/16/2024 | Buy Now | 162.51% | JP Morgan | Anupam Rama57% | $17 → $16 | Maintains | Overweight | Get Alert |
| 08/09/2024 | Buy Now | — | Needham | Gil Blum49% | — | Reiterates | → Hold | Get Alert |
| 05/30/2024 | Buy Now | 195.32% | Wells Fargo | — | → $18 | Initiates | → Overweight | Get Alert |
| 05/14/2024 | Buy Now | 113.29% | Guggenheim | Debjit Chattopadhyay50% | → $13 | Upgrade | Neutral → Buy | Get Alert |
| 05/10/2024 | Buy Now | 211.73% | UBS | Karl Chalabala28% | $20 → $19 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 211.73% | Morgan Stanley | Jeffrey Hung49% | $20 → $19 | Maintains | Overweight | Get Alert |
| 05/10/2024 | Buy Now | 113.29% | B of A Securities | Tazeen Ahmad53% | $14 → $13 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | — | Needham | Gil Blum49% | — | Reiterates | → Hold | Get Alert |
| 04/12/2024 | Buy Now | 129.7% | B of A Securities | Tazeen Ahmad53% | $16 → $14 | Maintains | Buy | Get Alert |
| 03/18/2024 | Buy Now | 211.73% | JP Morgan | Anupam Rama57% | $21 → $19 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 260.95% | Cantor Fitzgerald | Kristen Kluska66% | $22 → $22 | Reiterates | Overweight → Overweight | Get Alert |
| 12/19/2023 | Buy Now | 228.14% | Morgan Stanley | Jeffrey Hung49% | $15 → $20 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/09/2023 | Buy Now | 146.1% | Morgan Stanley | Andrew Galler33% | $14 → $15 | Maintains | Equal-Weight | Get Alert |
| 10/10/2023 | Buy Now | 129.7% | Morgan Stanley | Andrew Galler33% | $15 → $14 | Maintains | Equal-Weight | Get Alert |
| 09/29/2023 | Buy Now | 228.14% | UBS | Karl Chalabala28% | $19 → $20 | Maintains | Buy | Get Alert |
| 09/29/2023 | Buy Now | 211.73% | JP Morgan | Anupam Rama57% | $17 → $19 | Maintains | Overweight | Get Alert |
| 08/09/2023 | Buy Now | 211.73% | UBS | Karl Chalabala28% | $17 → $19 | Maintains | Buy | Get Alert |
| 07/11/2023 | Buy Now | 146.1% | Morgan Stanley | Andrew Galler33% | $15 → $15 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 04/24/2023 | Buy Now | 162.51% | B of A Securities | Tazeen Ahmad53% | $17 → $16 | Maintains | Buy | Get Alert |
| 03/28/2023 | Buy Now | 178.92% | B of A Securities | Tazeen Ahmad53% | $16 → $17 | Maintains | Buy | Get Alert |
| 03/02/2023 | Buy Now | 178.92% | UBS | Karl Chalabala28% | $15 → $17 | Maintains | Buy | Get Alert |
| 03/02/2023 | Buy Now | 80.48% | Goldman Sachs | Salveen Richter51% | $10 → $11 | Maintains | Neutral | Get Alert |
| 01/18/2023 | Buy Now | 162.51% | BTIG | Yun Zhong34% | $14 → $16 | Maintains | Buy | Get Alert |
| 11/08/2022 | Buy Now | 146.1% | Morgan Stanley | Andrew Galler33% | $14 → $15 | Maintains | Equal-Weight | Get Alert |
| 09/09/2022 | Buy Now | 129.7% | Morgan Stanley | Andrew Galler33% | → $14 | Initiates | → Equal-Weight | Get Alert |
FAQ
What is the target price for Amicus Therapeutics (FOLD) stock?
The latest price target for Amicus Therapeutics (NASDAQ:FOLD) was reported by UBS on May 2, 2025. The analyst firm set a price target for $22.00 expecting FOLD to rise to within 12 months (a possible 260.95% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Amicus Therapeutics (FOLD)?
The latest analyst rating for Amicus Therapeutics (NASDAQ:FOLD) was provided by UBS, and Amicus Therapeutics maintained their buy rating.
When was the last upgrade for Amicus Therapeutics (FOLD)?
The last upgrade for Amicus Therapeutics Inc happened on May 14, 2024 when Guggenheim raised their price target to $13. Guggenheim previously had a neutral for Amicus Therapeutics Inc.
When was the last downgrade for Amicus Therapeutics (FOLD)?
The last downgrade for Amicus Therapeutics Inc happened on December 13, 2024 when Morgan Stanley changed their price target from $17 to $12 for Amicus Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Amicus Therapeutics (FOLD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amicus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amicus Therapeutics was filed on May 2, 2025 so you should expect the next rating to be made available sometime around May 2, 2026.
Is the Analyst Rating Amicus Therapeutics (FOLD) correct?
While ratings are subjective and will change, the latest Amicus Therapeutics (FOLD) rating was a maintained with a price target of $21.00 to $22.00. The current price Amicus Therapeutics (FOLD) is trading at is $6.10, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
